Cargando…
Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study
BACKGROUND: Cancer and sepsis share risk factors, and sepsis patients may have impaired immune response and increased morbidity long after intensive care. This study aimed to assess whether sepsis survivors are at increased risk for cancer. Our objective was to assess the incidence of new cancer in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543324/ https://www.ncbi.nlm.nih.gov/pubmed/37773171 http://dx.doi.org/10.1186/s13054-023-04654-9 |
_version_ | 1785114276931829760 |
---|---|
author | Hästbacka, Johanna But, Anna Strandberg, Gunnar Lipcsey, Miklós |
author_facet | Hästbacka, Johanna But, Anna Strandberg, Gunnar Lipcsey, Miklós |
author_sort | Hästbacka, Johanna |
collection | PubMed |
description | BACKGROUND: Cancer and sepsis share risk factors, and sepsis patients may have impaired immune response and increased morbidity long after intensive care. This study aimed to assess whether sepsis survivors are at increased risk for cancer. Our objective was to assess the incidence of new cancer in 1-year sepsis survivors and test the hypothesis that it is higher than that of the general population. METHODS: We obtained data on ICU admissions of adult patients from Swedish Intensive care registry (SICR) from 2005 to 2017. We included patients with an explicit ICD-10 code for sepsis for the primary ICU admission. We obtained data on cancer diagnoses (2001–2018), death (2005–2018) and emigration (2005–2018) from Cancer and Cause of death and National Patient Registry databases of the National Board of Health and Welfare; age and sex-specific cancer incidence rates in Sweden from NORDCAN registry from 2006 to 2018. One-year survivors formed the final cohort, that was followed for new cancer diagnoses until death, emigration, or end of 2018, whichever came first. The main outcome measure was standardized incidence rate ratio (SIR) to compare the incidence of cancer in 1-year sepsis survivors to that in the general population (NORDCAN). We also performed several sensitivity analyses. RESULTS: In a cohort of 18,550 1-year survivors, 75,427 person years accumulated during a median follow-up (FU) of 3.36 years (IQR 1.72–5.86), 6366 (34.3%) patients died, and 1625 (8.8%) patients were diagnosed with a new cancer after a median FU of 2.51 (IQR 1.09–4.48) years. The incidence ratio of any new cancer over the whole FU was 1.31 (95% CI 1.23–1.40) for men and 1.74 (95% CI 1.61–1.88) for women. The difference in incidence rates persisted in several sensitivity analyses. The SIRs were highest in cancers of gastrointestinal tract, genital organs, and skin. CONCLUSION AND RELEVANCE: Compared to general population, incidence of cancer is increased in 1-year sepsis survivors. Variation in the findings depending on follow-up time suggests that factors other than sepsis alone are involved. Surveillance for malignant disease may be warranted in sepsis survivors. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04654-9. |
format | Online Article Text |
id | pubmed-10543324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105433242023-10-03 Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study Hästbacka, Johanna But, Anna Strandberg, Gunnar Lipcsey, Miklós Crit Care Research BACKGROUND: Cancer and sepsis share risk factors, and sepsis patients may have impaired immune response and increased morbidity long after intensive care. This study aimed to assess whether sepsis survivors are at increased risk for cancer. Our objective was to assess the incidence of new cancer in 1-year sepsis survivors and test the hypothesis that it is higher than that of the general population. METHODS: We obtained data on ICU admissions of adult patients from Swedish Intensive care registry (SICR) from 2005 to 2017. We included patients with an explicit ICD-10 code for sepsis for the primary ICU admission. We obtained data on cancer diagnoses (2001–2018), death (2005–2018) and emigration (2005–2018) from Cancer and Cause of death and National Patient Registry databases of the National Board of Health and Welfare; age and sex-specific cancer incidence rates in Sweden from NORDCAN registry from 2006 to 2018. One-year survivors formed the final cohort, that was followed for new cancer diagnoses until death, emigration, or end of 2018, whichever came first. The main outcome measure was standardized incidence rate ratio (SIR) to compare the incidence of cancer in 1-year sepsis survivors to that in the general population (NORDCAN). We also performed several sensitivity analyses. RESULTS: In a cohort of 18,550 1-year survivors, 75,427 person years accumulated during a median follow-up (FU) of 3.36 years (IQR 1.72–5.86), 6366 (34.3%) patients died, and 1625 (8.8%) patients were diagnosed with a new cancer after a median FU of 2.51 (IQR 1.09–4.48) years. The incidence ratio of any new cancer over the whole FU was 1.31 (95% CI 1.23–1.40) for men and 1.74 (95% CI 1.61–1.88) for women. The difference in incidence rates persisted in several sensitivity analyses. The SIRs were highest in cancers of gastrointestinal tract, genital organs, and skin. CONCLUSION AND RELEVANCE: Compared to general population, incidence of cancer is increased in 1-year sepsis survivors. Variation in the findings depending on follow-up time suggests that factors other than sepsis alone are involved. Surveillance for malignant disease may be warranted in sepsis survivors. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04654-9. BioMed Central 2023-09-29 /pmc/articles/PMC10543324/ /pubmed/37773171 http://dx.doi.org/10.1186/s13054-023-04654-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Hästbacka, Johanna But, Anna Strandberg, Gunnar Lipcsey, Miklós Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study |
title | Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study |
title_full | Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study |
title_fullStr | Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study |
title_full_unstemmed | Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study |
title_short | Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study |
title_sort | risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543324/ https://www.ncbi.nlm.nih.gov/pubmed/37773171 http://dx.doi.org/10.1186/s13054-023-04654-9 |
work_keys_str_mv | AT hastbackajohanna riskofmalignantdiseasein1yearsepsissurvivorsaregistrybasednationwidefollowupstudy AT butanna riskofmalignantdiseasein1yearsepsissurvivorsaregistrybasednationwidefollowupstudy AT strandberggunnar riskofmalignantdiseasein1yearsepsissurvivorsaregistrybasednationwidefollowupstudy AT lipcseymiklos riskofmalignantdiseasein1yearsepsissurvivorsaregistrybasednationwidefollowupstudy |